



(Translation of the original press release)

06<sup>th</sup> Jan 2025

HOIST Corporation

Representative chairman and CSO: Chihaya Kakinuma  
Executive Officer, Head of Management Division, CFO: Koji Abe  
(Representative phone number: 072-707-2760)

### **Publication regarding an efficient preparation method of Patient Derived Xenografts (PDX)**

We are pleased to inform the publication of a paper on Patient-derived cells (PDC) alongside Patient-derived xenografts (PDX) in the electronic version of Journal of Toxicologic Pathology<sup>1</sup>.

One of our executives is a co-author of the paper. PDC/PDX platform was launched in 2020 and we are currently providing service as a drug discovery technology.

The service provided by our company enables drug discovery using models that more closely resemble human cancer. This may lead to more efficient development of anticancer drugs, including improvement of the success rate of clinical studies, and applications in personalized medicine. In cooperation with medical institutions, we have an environment where tissue can be obtained immediately after extraction, leading to low passage number. In addition, we are able to provide additional information such as information about the genotype and treatment history, enabling a highly customized evaluation system.

In the report, we efficiently establish the PDX using hydrogel from frozen bladder cancer tissue. The result of the paper represents further development of our proprietary PDC/PDX technology, and we expect this technology to be of benefit to both our customers and our lead development programme, HM-001 (sodium chlorite).

---

<sup>1</sup> Please refer to the following website for the details of the publication:  
[https://www.jstage.jst.go.jp/article/tox/38/2/38\\_2024-0054/\\_article/-char/en](https://www.jstage.jst.go.jp/article/tox/38/2/38_2024-0054/_article/-char/en)